Melissa Bersanelli, Elena Verzoni, Alessio Cortellini, Raffaele Giusti, Lorenzo Calvetti, Paola Ermacora, Marilena Di Napoli, Annamaria Catino, Valentina Guadalupi, Giorgia Guaitoli, Vieri Scotti, Francesca Mazzoni, Antonello Veccia, Pamela Francesca Guglielmini, Fabiana Perrone, Marco Maruzzo, Ernesto Rossi, Chiara Casadei, Vincenzo Montesarchio, Francesco Grossi, Mimma Rizzo, Maria Grazia Travagliato Liboria, Manlio Mencoboni, Fable Zustovich, Lucia Fratino, Caterina Accettura, Saverio Cinieri, Andrea Camerini, Mariella Sorarù, Paolo Andrea Zucali, Serena Ricciardi, Antonio Russo, Giorgia Negrini, Maria Chiara Banzi, Gaetano Lacidogna, Giuseppe Fornarini, Letizia Laera, Claudia Mucciarini, Matteo Santoni, Claudia Mosillo, Andrea Bonetti, Lucia Longo, Donata Sartori, Editta Baldini, Michele Guida, Mauro Iannopollo, Roberto Bordonaro, Maria Francesca Morelli, Pierosandro Tagliaferri, Massimiliano Spada, Anna Ceribelli, Rosa Rita Silva, Franco Nolè, Giordano Beretta, Petros Giovanis, Daniele Santini, Stefano Luzi Fedeli, Oriana Nanni, Evaristo Maiello, Roberto Labianca, Carmine Pinto, Alberto Clemente, Michele Tognetto, Ugo De Giorgi, Sandro Pignata, Massimo Di Maio, Sebastiano Buti, Diana Giannarelli
BACKGROUND: The prospective multicentre observational INVIDIa-2 study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving immune checkpoint inhibitors (ICI). In this secondary analysis of the original trial, we aimed to assess the outcomes of patients to immunotherapy based on vaccine administration. METHODS: The original study enrolled patients with advanced solid tumours receiving ICI at 82 Italian Oncology Units from Oct 1, 2019, to Jan 31, 2020...
July 2023: EClinicalMedicine